SMEs in the pharmaceutical sector facing economic challenges
In an uncertain economic context, SMEs in the pharmaceutical sector are facing significant challenges. In 2022, ten markets accounted for 72.1% of the global pharmaceutical sector’s revenue. However, France, the fifth largest market globally, sees its SMEs, responsible for 35% of major therapeutic interest medications, struggling against rising inflation. Between public funding without guarantees of sustainability and fiscal pressures, these companies must find innovative solutions to remain competitive.
Tax incentives and public support for innovation
In 2020, the pharmaceutical sector benefited from nearly 710 million euros in research tax credits (CIR), representing 10% of the total CIR amount in France. This tax incentive is essential to encourage innovation, particularly among SMEs, which represented 91% of beneficiaries and 32% of the tax credit. Despite this support, France is losing ground on the international stage. To learn more about the specific challenges of the sector, click on this government strategy report.
Strategies for effective allocation of stakes
To counter this dynamic, SMEs in the pharmaceutical sector are increasingly turning to innovative strategies such as stake allocation to attract new investors. This approach not only strengthens their capital but also facilitates the implementation of new ecological measures, as stipulated in the agreement of October 17, 2023, on the ecological transition of the sector. For more information on tax practices and recommendations for strengthening the sector, see the analysis by La Tribune.
